Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-689 in Relapsed/Refractory Lymphomas
NCT03128164Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Aug 2017
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of amdizatinib in marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and 4 more (7 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Dose Limiting Toxicities at 28 days and Objective Response Rate at 1 year. Started Aug 2017; status: completed.
02
Drugs
amdizatinib
03
Conditions
marginal zone lymphoma (MZL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03128164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03128164.